The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Bio-Reference Laboratories Inc

Nasdaq: BRLI
Last

(U.S.) $28.43

Today's change-0.11 -0.39%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.
 

Bio-Reference Laboratories Inc

Nasdaq: BRLI
Last

(U.S.) $28.43

Today's change-0.11 -0.39%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Bio-Reference Laboratories Inc down (U.S.)$0.11

Bio-Reference Laboratories Inc closed lower Wednesday, dropping (U.S.)$0.11 or 0.39% to (U.S.)$28.43. Over the last five days, shares have gained 2.30% and 11.32% year to date. Shares have underperformed the S&P 500 by 39.35% during the last year.

Key company metrics

  • Open(U.S.) $28.61
  • Previous close(U.S.) $28.54
  • High(U.S.) $28.69
  • Low(U.S.) $28.15
  • Bid / Ask-- / --
  • YTD % change+11.32%
  • Volume138,970
  • Average volume (10-day)239,308
  • Average volume (1-month)213,066
  • Average volume (3-month)195,274
  • 52-week range(U.S.) $24.13 to (U.S.) $37.97
  • Beta0.87
  • Trailing P/E20.00×
  • P/E 1 year forward17.23×
  • Forward PEG1.67×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $1.42
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+4.97%

Based on its net profit margin of 4.97%, Bio-Reference Laboratories Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.67%Sector:HealthcareIndustry:Healthcare Facilities
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJul 31, 201407/31/2014Apr 30, 201404/30/2014Jan 31, 201401/31/2014Oct 31, 201310/31/2013
Revenue222201181192
Total other revenue--------
Total revenue222201181192
Gross profit102897285
Total cost of revenue120113109107
Total operating expense194182175172
Selling / general / administrative73686564
Research & development--------
Depreciation / amortization1211
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income2819620
Interest income (expense), net non-operating-1-1-1-1
Gain (loss) on sale of assets--------
Other--------
Income before tax2718520
Income after tax1510311
Income tax, total12829
Net income1510311
Total adjustments to net income--------
Net income before extra. items1510311
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1510311
Inc. avail. to common incl. extra. items1510311
Diluted net income1510311
Dilution adjustment--------
Diluted weighted average shares28282828
Diluted EPS excluding extraordinary itemsvalue per share0.550.370.110.40
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share0.550.370.110.40